K2Vital Delta (Menaquinone-7)

K2Vital Delta is a microencapsulated form of menaquinone-7 (MK-7), the long-chain vitamin K2 subtype that activates osteocalcin and matrix Gla protein (MGP) through gamma-carboxylation, directing calcium into bones while inhibiting arterial calcification. Its proprietary encapsulation technology enhances stability and bioavailability compared to standard MK-7 preparations.

Origin & History

K2Vital Delta is a branded, patented form of menaquinone-7 (MK-7), a subtype of vitamin K2, produced synthetically by Kappa BioSciences from flower extracts including geraniol and farnesol. This form contains 99.7% all-trans MK-7 in double-coated beadlets or spray-dried powder, distinguishing it from bacterial fermentation sources that may include cis isomers or impurities.

Historical & Cultural Context

Vitamin K2, including MK-7, lacks documented historical use in traditional medicine systems, being primarily a bacterial product found in fermented foods or derived from vitamin K1 in animal tissues. Vitamin K was discovered in 1929, with no pre-modern traditional context specified.

Health Benefits

• Supports bone health through γ-carboxylation of vitamin K-dependent proteins essential for calcium binding (mechanism established, no clinical trials provided)
• May benefit vascular health via extrahepatic tissue distribution (mechanism established, no clinical evidence provided)
• Enhanced bioavailability compared to vitamin K1 due to lipophilic properties and LDL transport (mechanistic evidence only)
• Potentially supports proper calcium metabolism in bones and blood vessels (theoretical based on mechanism)
• 99.7% pure all-trans form may offer superior stability compared to fermented sources (quality claim, no clinical comparison)

How It Works

Menaquinone-7 acts as a cofactor for gamma-glutamyl carboxylase (GGCX), the enzyme that converts glutamate residues to gamma-carboxyglutamate (Gla) on vitamin K-dependent proteins. This carboxylation activates osteocalcin to bind hydroxyapatite calcium in bone matrix and activates matrix Gla protein (MGP) in vascular smooth muscle cells to inhibit ectopic calcification. MK-7's long half-life of approximately 72 hours, relative to MK-4's 1–2 hours, allows sustained extrahepatic tissue distribution, reaching bone and arterial tissue more effectively than shorter-chain K2 isoforms.

Scientific Research

The research dossier contains no specific human clinical trials, RCTs, or meta-analyses for K2Vital Delta or MK-7. No PubMed PMIDs were provided in the search results, with only general mechanistic evidence referenced for bone and vascular health.

Clinical Summary

The most cited clinical evidence for MK-7 generally comes from a 3-year randomized controlled trial (MenaQ7 study, n=244 postmenopausal women) showing 180 mcg/day MK-7 significantly reduced loss of vertebral bone mineral content and improved carboxylated osteocalcin ratios compared to placebo. Separate research demonstrates MK-7 supplementation reduces desphospho-uncarboxylated MGP (dp-ucMGP), a validated biomarker of arterial calcification risk, in dose-dependent fashion. K2Vital Delta specifically has been studied for its improved oxidative stability in food and supplement matrices, though published randomized trials using K2Vital Delta as the named ingredient are limited. Overall evidence quality for MK-7 in bone health is moderate; vascular endpoint data remains largely biomarker-driven without large-scale fracture or cardiovascular event trials.

Nutritional Profile

K2Vital Delta is a microencapsulated form of menaquinone-7 (MK-7), a long-chain form of vitamin K2. Active compound: all-trans menaquinone-7 (C46H64O2, MW 649.0 g/mol). Typical standardization: minimum 0.2% MK-7 (approximately 2,000 µg MK-7 per gram of product) in microencapsulated beadlet form. The 'Delta' designation refers to the proprietary microencapsulation technology using a matrix of modified starch, sucrose, and antioxidants (such as ascorbyl palmitate and dl-alpha-tocopherol) to protect MK-7 from degradation when combined with minerals (especially calcium and magnesium), which are known to degrade unprotected MK-7. Contains no significant macronutrients (protein, fat, carbohydrate, or fiber) at functional dosing levels. Typical supplemental dose delivers 75–200 µg MK-7 per serving. Bioavailability notes: MK-7 has a substantially longer half-life (~72 hours) compared to vitamin K1 (~1–2 hours) and shorter-chain menaquinones, due to its high lipophilicity and preferential transport via low-density lipoproteins (LDL) rather than triglyceride-rich lipoproteins. This LDL-mediated transport facilitates distribution to extrahepatic tissues including bone and vasculature. The microencapsulation in K2Vital Delta preserves all-trans MK-7 stability (>95% retention over shelf life) even in the presence of alkaline minerals, ensuring consistent bioactive delivery. Fat co-ingestion modestly enhances absorption but is not strictly required due to MK-7's inherent lipophilicity. All-trans isomer content is critical for bioactivity; cis-isomers are biologically inactive, and K2Vital Delta maintains high all-trans purity (typically ≥98%). No vitamins, minerals, or other micronutrients are present in meaningful quantities beyond vitamin K2 as MK-7. Produced via fermentation-derived or synthetic pathways (Kappa Bioscience, Norway).

Preparation & Dosage

No clinically studied dosage ranges, forms, or standardization details are provided in the research results for K2Vital Delta or MK-7. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Vitamin D3, Calcium, Magnesium, Vitamin K1, Boron

Safety & Interactions

MK-7 at doses up to 360 mcg/day has not demonstrated toxicity in published studies and carries no established tolerable upper intake level from regulatory bodies such as EFSA. The most significant drug interaction is with vitamin K antagonist anticoagulants (warfarin, acenocoumarol), where MK-7 can substantially reduce anticoagulant efficacy due to its prolonged half-life — patients on these medications should avoid supplemental MK-7 without physician oversight. Individuals taking other anticoagulants such as direct oral anticoagulants (DOACs, e.g., apixaban, rivaroxaban) face a lower but still advisable need for medical consultation before use. Safety data in pregnancy and lactation is insufficient; supplementation beyond dietary amounts is not routinely recommended during pregnancy without medical guidance.